Debt-free Balance SheetA debt-free balance sheet with substantial equity provides durable financial flexibility. It reduces refinancing and interest risk, serves as a cushion while the company addresses cash burn, and allows management to fund R&D or operations without immediate external leverage.

Exceptionally High Gross MarginsNear-97% gross margins indicate strong unit economics consistent with software or digital-health services. High margins create scalable operating leverage: as revenue grows, incremental contribution to profitability is large, supporting a durable path to operating profitability if OPEX growth is controlled.

Revenue Growth MomentumA return to revenue growth after a prior decline, plus high reported multi-period growth metrics, suggests the business can reaccelerate adoption. Sustained top-line growth supports scale, better fixed-cost absorption, and is a lasting fundamental lever for improving margins over months.

Bears Say

Deep Net LossesPersistently large net losses indicate the company remains far from profitable and must materially cut costs or increase revenue to reach breakeven. Extended losses erode equity, limit reinvestment capacity, and force reliance on financing or dilution absent a durable turnaround.

Accelerating Cash BurnWorsening negative operating and free cash flows show the business is consuming cash at an accelerating rate. This structural cash burn raises liquidity risk over months, increases dependency on external capital, and constrains strategic choices unless cash generation reverses.

Negative Returns And Eroding EquityNegative ROE and declining equity reflect that investments have not generated shareholder returns and that losses are depleting the balance sheet. Over time this hampers ability to self-fund growth, raises governance scrutiny, and increases the likelihood of future capital raises or dilution.

4263 FAQ

What was SUSMED,Inc.’s price range in the past 12 months?

SUSMED,Inc. lowest stock price was ¥413.00 and its highest was ¥1129.00 in the past 12 months.

What is SUSMED,Inc.’s market cap?

SUSMED,Inc.’s market cap is ¥15.59B.

When is SUSMED,Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were SUSMED,Inc.’s earnings last quarter?

Currently, no data Available

Is SUSMED,Inc. overvalued?

According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SUSMED,Inc. pay dividends?

SUSMED,Inc. does not currently pay dividends.

What is SUSMED,Inc.’s EPS estimate?

SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SUSMED,Inc. have?

SUSMED,Inc. has 16,868,100 shares outstanding.

What happened to SUSMED,Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of SUSMED,Inc.?

Currently, no hedge funds are holding shares in JP:4263

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SUSMED,Inc.

SUSMED, Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. The company also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, it offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.